Marketing authorisation holders may subcontract certain activities of the pharmacovigilance system to third parties, for example to specialised service providers. Where the pharmacovigilance tasks have been subcontracted by the marketing authorisation holder to a third party (or by this third party to another third party), delegation arrangements, each party’s responsibilities, and audit and inspection arrangements should be clearly documented. Third parties should agree to be audited by or on behalf of marketing authorisation holders and inspected by the competent authorities in order to guarantee and verify compliance concerning all aspects of the pharmacovigilance system.
Recital 3, Regulation (EU) 2025/1466
In forcesince 22 Jul 2025